According to a recent LinkedIn post from PictorLabs, the company is featuring its virtual staining technology in a session at the DPAI 2026 meeting hosted at The Ohio State University. The session, led by the firm’s VP of Product Megan Rothney, Ph.D., is described as focused on integrating virtual staining into real-world pathology workflows.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights use cases including virtual H&E from unstained tissue, virtual special stains and IHC derived from existing H&E slides, and validation against conventional staining methods. It also emphasizes how reviewing morphology prior to molecular workflows could change tissue utilization, particularly in settings where sample quantity is constrained.
For investors, this conference presence suggests PictorLabs is targeting adoption among digital and computational pathology users and aligning its tools with molecular pathology workflows. While the technology is described as for research use only and not FDA cleared or approved, early engagement with academic and clinical researchers could support future commercialization pathways and strengthen the company’s competitive position in AI-enabled pathology.